Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus

International Journal of Biochemistry and Cell Biology

Volumn 38, Issue 5-6, 2006, Pages 845-859

  León, Diva D De ^a,b   Crutchlow, Michael F ^a   Ham, Jee Young Nina ^a,b   Stoffers, Doris A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Cells; Diabetes; GLP 1; Glucose; Insulin

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ALBUGON; CJC 1131; EXENDIN 4; G PROTEIN COUPLED RECEPTOR; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; ISOLEUCINE THIAZOLIDIDE; LIRAGLUTIDE; RECOMBINANT GLUCAGON LIKE PEPTIDE 1; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

APOPTOSIS; B LYMPHOCYTE; BRAIN STEM; CARBOHYDRATE METABOLISM; CELL DIFFERENTIATION; CELL DIVISION; DIABETES MELLITUS; DRUG HALF LIFE; GLUCAGON RELEASE; GLUCOSE TRANSPORT; HUMAN; HYPOTHALAMUS; INSULIN RELEASE; INTESTINE; NAUSEA; NONHUMAN; PANCREAS ISLET ALPHA CELL; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; SATIETY; STOMACH EMPTYING; VOMITING;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HOMEOSTASIS; HUMANS; MALEIMIDES; MOLECULAR SEQUENCE DATA; NITRILES; PEPTIDES; PROTEASE INHIBITORS; PYRROLIDINES; RECEPTORS, GLUCAGON; VENOMS;

EID: 33644840976     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2005.07.011     Document Type: Review

References (168)

1. E.J. Abraham, C.A. Leech, J.C. Lin, H. Zulewski, and J.F. Habener Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells Endocrinology 143 8 2002 3152 3161
2. A. Acitores, N. Gonzalez, V. Sancho, I. Valverde, and M.L. Villanueva-Penacarrillo Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle J. Endocrinol. 180 2004 389 398
3. H. Agerso, L.B. Jensen, B. Elbrond, P. Rolan, and M. Zdravkovic The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men Diabetologia 45 2002 195 202
4. U. Ahlgren, J. Jonsson, L. Jonsson, K. Simu, and H. Edlund Beta-cell-specific inactivation of the mouse Ipf 1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes Genes Dev. 12 1998 1763 1768
5. B. Ahren GLP-1 and extra-islet effects Horm. Metab. Res. 36 2004 842 845
6. B. Ahren, R. Gomis, E. Standl, D. Mills, and A. Schweizer Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes Diab. Care 27 2004 2874 2880
7. B. Ahren, and O. Schmitz GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes Horm. Metab. Res. 36 2004 867 876
8. B. Ahren, M. Landin-Olsson, P.A. Jansson, M. Svensson, D. Holmes, and A. Schweizer Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes J. Clin. Endocrinol. Metab. 89 2004 2078 2084
9. B. Ahren, E. Simonsson, H. Larsson, M. Landin-Olsson, H. Torgeirsson, and P.A. Jansson Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes Diab. Care 25 2002 869 875
10. A.I. Alcantara, M. Morales, E. Delgado, M.I. Lopez-Delgado, F. Clemente, and M.A. Luque Exendin-4 agonist and exendin (9-39) amide antagonist of the GLP-1(7-36) amide effects in liver and muscle Arch. Biochem. Biophys. 341 1997 1 7
11. E. Alvarez, M.D. Martinez, I. Roncero, J.A. Chowen, B. Garcia-Cuartero, and J.D. Gispert The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem J. Neurochem. 92 2005 798 806
12. E. Alvarez, J. Romero, J.A. Chowen, and B. Thorens Expression of the glucagon-like peptide-1 receptor gene in rat brain J. Neurochem. 66 1996 920 927
13. Y. Anini, and P.L. Brubaker Muscarinic receptors control glucagon-like peptide-1 secretion by human endocrine L-cells Endocrinology 144 2003 3244 3250
14. Y. Anini, T. Hansotia, and P.L. Brubaker Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats Endocrinology 143 2002 2420 2426
15. L.L. Baggio, Q. Huang, T.J. Brown, and D.J. Drucker A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis Diabetes 53 2004 2492 2500
16. L. Baggio, T.J. Kieffer, and D.J. Drucker Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice Endocrinology 141 10 2000 3703 3709
17. H.J. Balks, J.J. Holst, A. von zur Muhlen, and G. Brabant Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors J. Clin. Endocrinol. Metab. 82 1997 786 790
18. E. Bertin, P. Arner, J. Bolinder, and E. Hagstrom-Toft Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo J. Clin. Endocrinol. Metab. 86 2001 1229 1234
19. M. Bloom, J. Bock, A. Duttaroy, K. Grzegorzewski, P. Moore, and Y. Ou Albugon™ fusion protein: a long-acting analog of GLP-1 that provides lasting antidiabetic effect in animals A.D. Association American Diabetes Association's 63rd Annual Meetings (Vol. Abstract 634) New Orleans 2003
20. Z.T. Bloomgarden Gut-derived incretin hormones and new therapeutic approaches Diab. Care 27 2004 2554 2559
21. J.C. Brown, V. Mutt, and R.A. Pederson Further purification of a polypeptide demonstrating enterogastrone activity J. Physiol. 209 1970 57 64
22. P.L. Brubaker Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides Endocrinology 128 1991 3175 3182
23. P.L. Brubaker, and Y. Anini Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2 Can. J. Physiol. Pharmacol. 81 2003 1005 1012
24. P.L. Brubaker, and D.J. Drucker Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors Receptors Channels 8 2002 179 188
25. B.P. Bullock, R.S. Heller, and J.F. Habener Tissue distribution of messenger ribonuclei acid encoding the rat glucagon-like peptide 1 receptor Endocrinology 137 1996 2968 2978
26. J.B. Buse, R.R. Henry, J. Han, D.D. Kim, M.S. Fineman, and A.D. Baron Effects of exenatide. (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diab. Care 27 2004 2628 2635
27. J. Buteau, W. El-Assaad, C.J. Rhodes, L. Rosenberg, E. Joly, and M. Prentki Glucagon-like peptide-1 prevents beta cell glucolipotoxicity Diabetologia 47 2004 806 815
28. A.E. Byrnes, G.S. Frost, C.M. Edwards, M.A. Ghatei, and S.R. Bloom Plasma glucagon-like peptide-1 (7-36) amide (GLP-1) response to liquid phase, solid phase, and meals of differing liquid composition Nutrition 4 1998 433 436
29. R.V. Campos, Y.C. Lee, and D.J. Drucker Divergent tissue-specific and developmental expression of receptors for glucagon-like peptide-1 in the mouse Endocrinology 134 1994 2156 2164
30. A.M. Chang, G. Jakobsen, J. Sturis, M.J. Smith, C.J. Bloem, and B. An The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose Diabetes 52 2003 1786 1791
31. A.T. Cheung, B. Dayanandan, J.T. Lewis, G.S. Korbutt, R.V. Rajotte, and M. Bryer-Ash Glucose-dependent insulin release from genetically engineered K cells Science 290 2000 1959 1962
32. W. Creutzfeldt The [pre-] history of the incretin concept Regul. Pept. 128 2005 87 91
33. D.A. D'Alessio, W.Y. Fujimoto, and J.W. Ensinck Effects of glucagonlike peptide I- (7-36) on release of insulin, glucagon, and somatostatin by rat pancreatic islet cell monolayer cultures Diabetes 38 1989 1534 1538
34. D.A. D'Alessio, T. Vahl, and R. Prigeon Effects of glucagon-like peptide 1 on the hepatic glucose metabolism Horm. Metab. Res. 36 2004 837 841
35. D.A. D'Alessio, R. Vogel, R. Prigeon, E. Laschansky, D. Koerker, and J. Eng Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons J. Clin. Invest. 97 1 1996 133 138
36. D. Dardevet, M.C. Moore, D. Neal, C.A. DiCostanzo, W. Snead, and A.D. Cherrington Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region Am. J. Physiol. Endocrinol. Metab. 287 2004 E75 E81
37. D.D. De Leon, S. Deng, R. Madani, R.A. Ahima, D.J. Drucker, and D.A. Stoffers Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy Diabetes 52 2003 365 371
38. 2-terminus in type II diabetic patients and in healthy subjects Diabetes 44 1995 1126 1131
39. K.B. Degn, B. Brock, C.B. Juhl, C.B. Djurhuus, J. Grubert, and D. Kim Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia Diabetes 53 2004 2397 2403
40. K.B. Degn, C.B. Juhl, J. Sturis, G. Jakobsen, B. Brock, and V. Chandramouli One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24 h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes Diabetes 53 2004 1187 1194
41. N.M. Doliba, W. Qin, M.Z. Vatamaniuk, C. Li, D. Zelent, and H. Najafi Restitution of defective glucose-stimulated insulin release of sulfonylurea type 1 receptor knockout mice by acetylcholine Am. J. Physiol. Endocrinol. Metab. 286 5 2004 E834-E843
42. D.J. Drucker Glucagon-like peptide: regulators of cell proliferation, differentiation, and apoptosis Mol. Endocrinol. 17 2 2003 161 171
43. D.J. Drucker, J. Philippe, S. Mojsov, W.L. Chick, and J.F. Habener Glucagon-like peptide-I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line PNAS 84 1987 3434 3438
44. J. Dupre, S.A. Ross, D. Watson, and J.C. Brown Stimulation of insulin secretion by gastric inhibitory polypeptide in man J. Clin. Endocrinol. Metab. 37 1973 826 828
45. C.M. Edwards, S.A. Stanley, R. Davis, A.E. Brynes, G.S. Frost, and L.J. Seal Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers Am. J. Physiol. Endocrinol. Metab. 281 2001 E155 E161
46. C.M.B. Edwards, J.F. Todd, M. Mahmoudi, Z. Wang, R.M. Wang, and M.A. Ghatei Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39 Diabetes 48 1999 86 93
47. J.M. Egan, A. Bulotta, H. Hui, and R. Perfetti GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells Diab. Metab. Res. Rev. 19 2003 115 123
48. J.M. Egan, A.R. Clocquet, and D. Elahi The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes J. Clin. Endocrinol. Metab. 87 2002 1282 1290
49. J.M. Egan, C. Montrose-Rafizadeh, Y. Wang, M. Bernier, and J. Roth Glucagon-like peptide-1 [7-36 amide] (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of the several potential extrapancreatic sites of GLP-1 action Endocrinology 135 1994 2070 2075
50. R. Eissele, R. Goke, S. Willemer, H.P. Harthus, H. Vermeer, and R. Arnold Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man Eur. J. Clin. Invest. 22 1992 283 291
51. D. Elahi, M. McAloon Dyke, N.K. Fukagawa, G.S. Meneilly, A.L. Sclater, and K.L. Minaker The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects Regul. Pept. 51 1994 63 74
52. B. Elbrond, G. Jakobsen, S. Larsen, H. Agerso, L.B. Jensen, and P. Rolan Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects Diab. Care 25 2002 1398 1404
53. R.M. Elliott, L.M. Morgan, J.A. Tredger, S. Deacon, J. Wright, and V. Marks Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24 h secretion patterns J. Endocrinol. 138 1993 159 166
54. H. Elrick, L. Stimmler, C.J. Hlad, and Y. Arai Plasma insulin responses to oral and intravenous glucose administration J. Clin. Endocrinol. Metab. 24 1964 1076 1082
55. J. Eng, W.A. Kleinman, L. Singh, G. Singh, and J.P. Raufman Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas J. Biol. Chem. 267 1992 7402 7405
56. L. Farilla, A. Bulotta, B. Hirshberg, S. Li Calzi, N. Khoury, and H. Noushmehr Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets Endocrinology 144 2003 5149 5158
57. L. Farilla, H. Hui, C. Bertolotto, E. Kang, A. Bulotta, and U. Di Mario Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats Endocrinology 143 2002 4397 4408
58. H.C. Fehmann, R. Goke, and B. Goke Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide Endocr. Rev. 16 1995 390 410
59. H.C. Fehmann, and J.F. Habener Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells Endocrinology 130 1992 159 166
60. M.S. Fineman, T.A. Bicsak, L.Z. Shen, K. Taylor, E. Gaines, and A. Varns Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes Diab. Care 26 2003 2370 2377
61. M.S. Fineman, L.Z. Shen, K. Taylor, D.D. Kim, and A.D. Baron Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes Diab. Metab. Res. Rev. 20 2004 411 417
62. A. Flint, A. Raben, A. Astrup, and J.J. Holst Glucagon-like peptide-1 promotes satiety and suppressses energy intake in humans J. Clin. Invest. 101 1998 515 520
63. A. Flint, A. Raben, A.K. Ersboll, J.J. Holst, and A. Astrup The effect of physiologic levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity Int. J. Obes. 25 2001 781 792
64. P. Guivarc'h, J. Castaigne, C. Gagnon, L. Peslherbe, J.H. Dreyfus, and D.J. Drucker CJC-1131, a long acting GLP-1 analog safely normalized post-prandial glucose excursion and fasting glycemia in type 2 diabetes mellitus American Diabetes Association's 64th Annual Meeting (Vol. Abstract 535) Orlando, FL: American Diabetes Association 2004
65. M. Gutniak, C. Orskov, J.J. Holst, B. Ahren, and S. Efendic Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus N. Engl. J. Med. 326 1992 1316 1322
66. M. Gutniak, J. Svartberg, P.M. Hellstrom, J.J. Holst, N. Adner, and B. Ahren Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes Int. J. Med. 250 2001 81 87
67. J.P. Gutzwiller, J. Drewe, B. Goke, H. Schmidt, B. Rohrer, and J. Lareida Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2 Am. J. Physiol. 276 1999 R1541 R1544
68. J.P. Gutzwiller, B. Goke, J. Drewe, P. Hildebrand, S. Ketterer, and D. Handschin Glucagon-like peptide-1: a potent regulator of food intake in humans Gut 44 1999 81 86
69. T. Hansotia, L.L. Baggio, D. Delmeire, S.A. Hinke, Y. Yamada, and K. Tsukiyama Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors Diabetes 53 2004 1326 1335
70. T. Hansotia, and D.J. Drucker GIP and GLP-1 as incretin hormones: Lessons from single and double incretin receptor knockout mice Regul. Pept. 128 2005 125 134
71. J.-C. Henquin, C. Boitard, E. Ferrannini, D.F. Steiner, and S. Efendic Editorial: Impact of treatment on islet function in type 2 diabetes Diabetes 53 2004 S1 S5
72. C. Hermann, R. Goke, G. Richter, H.C. Fehmann, R. Arnold, and B. Goke Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients Digestion 56 1995 117 126
73. J.J. Holst, and C. Orskov The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism Diabetes 53 3 2004 S197-S204
74. H. Hui, A. Nourparvar, X. Zhao, and R. Perfetti Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway Endocrinology 144 2003 1444 1455
75. H. Hui, C. Wright, and R. Perfetti Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1 -positive pancreatic ductal cells into insulin-secreting cells Diabetes 50 4 2001 785 796
76. N. Imeryuz, B.C. Yegen, A. Bozkurt, T. Coskun, M.L. Villanueva- Penacarrillo, and N.B. Ulusoy Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms Am. J. Physiol. 273 1997 G920 G927
77. L.I. Jepeal, Y. Fujitani, M.O. Boylan, C.N. Wilson, C.V. Wright, and M.M. Wolfe Cell-specific expression of glucose-dependent-insulinotropic polypeptide is regulated by the transcription factor PDX-1 Endocrinology 146 2005 383 391
78. U.S. Jhala, G. Canettieri, R.A. Screaton, R.N. Kulkarni, S. Krajewski, and J. Reed cAMP promotes pancreatic (β-cell survival via CREB-mediated induction of IRS2 Genes Dev. 17 2003 1575 1580
79. J. Jonsson, L. Carlsson, T. Edlund, and H. Edlund Insulin-promoter factor I is required for pancreas development in mice Nature 371 1994 606 609
80. S.V. Joy, P.T. Rodgers, and A.C. Scates Incretin mimetics as emerging treatments for type 2 diabetes Ann. Pharmacother. 39 2005 110 118
81. C.B. Juhl, M. Hollingdal, J. Sturis, G. Jakobsen, H. Agerso, and J. Veldhuis Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes Diabetes 51 2002 424 429
82. Y. Kashima, T. Miki, T. Shibasaki, N. Ozaki, M. Miyazaki, and H. Yano Critical role of cAMP-GEFII-Rim2 complex in incretin-potentiated insulin secretion J. Biol. Chem. 276 2001 46046 46053
83. T.J. Kieffer, C.H. McIntosh, and R.A. Pederson Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 1995 3585 3596
84. J.G. Kim, L.L. Baggio, D.P. Bridon, J.P. Castaigne, M.F. Robitaille, and L. Jette Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo Diabetes 52 2003 751 759
85. L.B. Knudsen, P.F. Nielsen, P.O. Huusfeldt, N.L. Johansen, K. Madsen, and F.Z. Pedersen Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration J. Med. Chem. 43 2000 1664 1669
86. O.G. Kolterman, J.B. Buse, M.S. Fineman, E. Gaines, S. Heintz, and T.A. Bicsak Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes J. Clin. Endocrinol. Metab. 88 2003 3082 3089
87. B. Kreymann, G. Williams, M.A. Ghatei, and S.R. Bloom Glucagon-like peptide 1 7-36: a physiological incretin in man Lancet 2 1987 1300 1304
88. P.J. Larsen, C. Fledelius, L.B. Knudsen, and M. Tang-Christensen Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats Diabetes 50 2001 2530 2539
89. J. Larsen, B. Hylleberg, K. Ng, and P. Damsbo Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment Diab. Care 24 2001 1416 1421
90. P.J. Larsen, M. Tang-Christensen, J.J. Holst, and C. Orskov Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem Neuroscience 77 1997 257 370
91. L.I. Larsson, O.D. Madsen, P. Serup, J. Jonsson, and H. Edlund Pancreatic homeobox 1: role in gastric endocrine pattering Mech. Dev. 60 1996 175 184
92. B. Lawrence, J.F. Dreyfus, S. Wen, P.H. Guivarc'h, D.J. Drucker, and J.P. Castaigne CJC 1131 a long acting GLP-1 derivative exhibits an extended pharmacokinetic profile in healthy human volunteers American Diabetes Association 63rd Annual Meeting 534-P New Orleans, Louisiana: American Diabetes Association 2003 A125
93. Y. Li, X. Cao, L.X. Li, P.L. Brubaker, H. Edlund, and D.J. Drucker β-cell PDX expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1 Diabetes 54 2005 482 491
94. Y. Li, T. Hansotia, B. Yusta, F. Ris, P.A. Halban, and D.J. Drucker Glucagon-like peptide- 1 receptor signaling modulates beta cell apoptosis J. Biol. Chem. 278 1 2003 471 478
95. Z. Ling, D. Wu, Y. Zambre, D. Flamez, D.J. Drucker, and D. Pipeleers Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice Virchows Arch. 438 2001 382 387
96. M. Luque, N. Gonzalez, L. Marquez, A. Acitores, A. Redondo, and M. Morales Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes J. Endocrinol. 173 2002 465 473
97. P.E. MacDonald, W. El-Kholy, M.J. Riedel, A.M. Salapatek, P.E. Light, and M.B. Wheeler The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion Diabetes 51 Suppl. 3 2002 S434 S442
98. P.E. MacDonald, A.M. Salapatek, and M.B. Wheeler Glucagon-like peptide-1 receptor activation antagonizes voltage-dependent repolirizing K (+) currents in beta-cells: a possible glucose-dependent insulinotropic mechanism Diabetes 51 Suppl. 3 2002 S443 S447
99. S. Madsbad, O. Schmitz, J. Ranstam, G. Jakobsen, and D.R. Matthews Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide. (NN2211): a 12-week, double-blind, randomized, controlled trial Diab. Care 27 2004 1335 1342
100. N. McIntyre, C.D. Holdsworth, and D.A. Turner New interpretation of oral glucose tolerance Lancet 2 1964 20 21
101. K. Meeran, D. O'Shea, C.M. Edwards, M.D. Turton, M.M. Heath, and I. Gunn Repeated intracerebroventricular administration of glucagon-like peptide-1 (7-36) amide or exendin-(9-39) alters body weight in the rat Endocrinology 140 1999 244 250
102. R. Mentlein Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides Regul. Pept. 85 1999 9 24
103. I. Merchenthaler, M. Lane, and P. Shughrue Distribution of pre-pro-glucagon and glucagons like peptide-1 receptor messenger RNAs in the rat central nervous system J. Comp. Neurol. 403 1999 261 280
104. J. Miholic, C. Orskov, J.J. Holst, J. Kotzerke, and H.J. Meyer Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy Dig. Dis. Sci. 36 10 1991 1361 1370
105. K. Montersen, L.L. Christensen, J.J. Holst, and C. Orskov GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine Regul. Pept. 114 2003 189 196
106. C. Montrose-Rafizadeh, H. Yang, B.D. Rodgers, A. Beday, L.A. Pritchette, and J. Eng High potency antagonists of the pancreatic glucagon-like peptide-1 receptor J. Biol. Chem. 272 34 1997 21201 21206
107. C. Montrose-Rafizadeh, H. Yang, Y. Wang, J. Roth, M.H. Montrose, and L.G. Adams Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes J. Cell. Physiol. 172 1997 275 283
108. L. Morgan, R. Elliott, J. Tredger, J. Nightingale, and V. Marks GLP-1 secretion in response to nutrients in man Digestion 54 1993 374 376
109. H. Nakabayashi, M. Nishizawa, A. Nakagawa, R. Takeda, and A. Niijima Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1 Am. J. Physiol. 271 1996 E808 E813
110. E. Naslund, M. Gutniak, S. Skogar, S. Rossner, and P.M. Hellstrom Glucagon-lieke peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men Am. J. Clin. Nutr. 68 1998 525 530
111. D.M. Nathan, E. Schreiber, H. Fogel, S. Mojsov, and J.F. Habener Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects Diab. Care 15 1992 270 276
112. M.A. Nauck Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes Horm. Metab. Res. 36 2004 852 858
113. M.A. Nauck, A. El-Ouaghlidi, B. Gabrys, K. Hucking, J.J. Holst, and C.F. Deacon Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes Regul. Pept. 122 2004 209 217
114. M.A. Nauck, M.M. Heimesaat, C. Orskov, J.J. Holst, R. Ebert, and W. Creutzfeldt Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus J. Clin. Invest. 91 1 1993 301 307
115. M.A. Nauck, E. Homberger, E.G. Siegel, R.C. Allen, R.P. Eaton, and R. Ebert Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide and insulin responses J. Clin. Endocrinol. Metab. 63 1986 492 498
116. M.A. Nauck, and J.J. Meier Glucagon-like peptide 1 and its derivatives in the treatment of diabetes Regul. Pept. 128 2005 135 148
117. M.A. Nauck, U. Niedereichholz, R. Ettler, J.J. Holst, C. Orskov, and R. Ritzel Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans Am. J. Physiol. 273 1997 E981 E988
118. M.A. Nauck, F. Stockman, R. Ebert, and W. Creutzfeldt Reduced incretin effect in type 2 (non-insulin-dependent) diabetes Diabetologia 29 1 1986 46 52
119. M. Nishizawa, H. Nakabayashi, K. Kawai, T. Ito, S. Kawakami, and A. Nakagawa The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor J. Auton. Nerv. Syst. 80 2000 14 21
120. B. Nyholm, M. Walker, C.H. Gravholt, P.A. Shearing, J. Sturis, and K.G.M.M. Alberti Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of type II (non-insulin-dependent) diabetic parents: evidence of several aberrations Diabetologia 42 1999 1314 1323
121. M.F. Offield, T.L. Jetton, P.A. Labosky, M. Ray, R.W. Stein, and M.A. Magnuson PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum Development 122 1996 983 995
122. K. Prasadan, E. Daume, B. Preuett, T. Spilde, A. Bhatia, and H. Kobayashi Glucagon is required for early insulin-positive differentiation in the developing mouse pancreas Diabetes 51 2002 3229 3236
123. R.L. Prigeon, S. Quddusi, B. Paty, and D.A. D'Alessio Suppression of endogenous glucose production by glucagon-like peptide 1 independent of islet hormones: a novel extrapancreatic effect Am. J. Physiol. 285 2003 E701 E707
124. J. Rachman, B.A. Barrow, J.C. Levy, and R.C. Turner Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM Diabetologia 40 1997 205 211
125. F. Reimann, and F.M. Gribble Glucose-sensing in glucagon-like peptide-1-secreting cells Diabetes 51 2002 2757 2763
126. F. Reimann, L. Williams, G. Da Silva Xavier, G.A. Rutter, and F.M. Gribble Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells Diabetologia 47 9 2004 1592 1601
127. J.N. Roberge, and P.L. Brubaker Regulation of intestinal proglucagon-dericed peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop Endocrinology 133 1993 233 240
128. J.N. Roberge, K.A. Gronau, and P.L. Brubaker Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut Endocrinology 137 1996 2383 2388
129. A.S. Rocca, and P.L. Brubaker Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion Endocrinology 140 1999 1687 1694
130. B. Rolin, M.O. Larsen, C.F. Gotfredsen, C.F. Deacon, R.D. Carr, and M. Wilken The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice Am. J. Physiol. Endocrinol. Metab. 283 2002 E745 E752
131. C. Ruiz-Grande, C. Alarcon, A. Alcantara, C. Castilla, J.M. Lopez Novoa, and M.L. Villanueva-Penacarrillo Renal catabolism of truncated glucagon-like peptide 1 Horm. Metab. Res. 25 1993 612 616
132. C. Ruiz-Grande, C. Alarcon, E. Merida, and I. Valverde Lipolytic action of glucagon-like peptides in isolated rat adipocytes Peptides 13 1992 13 16
133. J. Schirra, K. Sturm, P. Leicht, R. Arnold, B. Goke, and M. Katschinski Exendin (9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans J. Clin. Invest. 101 7 1998 1421 1430
134. W.E. Schmidt, E.G. Siegel, and W. Creutzfeldt Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets Diabetologia 28 1985 704 707
135. R.A. Screaton, M.D. Conkright, Y. Katoh, J.L. Best, G. Canettieri, and S. Jeffries The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector Cell 119 2004 61 74
136. L.A. Scrocchi, T.J. Brown, N. MaClusky, P.L. Brubaker, A.B. Auerbach, and A.L. Joyner Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene Nat. Med. 2 11 1996 1254 1258
137. I. Shimizu, M. Hirota, C. Ohjboshi, and K. Shima Identification and localization of glucagon-like peptide 1 and its receptor in rat brain Endocrinology 121 1987 1076 1082
138. 2+ in two enteroendocrine cell lines, STC-1 and GLUTag J. Physiol. 528 2000 165 176
139. D.A. Stoffers The development of beta-cell mass: recent progress and potential role of GLP-1 Horm. Metab. Res. 36 2004 811 821
140. D.A. Stoffers, B.M. Desai, D.D. DeLeon, and R.A. Simmons Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat Diabetes 52 2003 734 740
141. D.A. Stoffers, T.J. Kieffer, M.A. Hussain, D.J. Drucker, S. Bonner-Weir, and J.F. Habener Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas Diabetes 49 2000 741 748
142. D.A. Stoffers, N.T. Zinkin, V. Stanojevic, W.L. Clarke, and J.F. Habener Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence Nat. Genet. 15 1997 106 110
143. M. Szayna, M.E. Doyle, J.A. Betkey, H.W. Holloway, R.G. Spencer, and N.H. Greig Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats Endocrinology 141 2000 1936 1941
144. B.A.P. Thorens, L. Buhler, S.P. Deng, P. Morel, and C. Widman Cloning and functional expression of the human islet GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor Diabetes 42 1993 1678 1682
145. J.F. Todd, J.P. Wilding, C.M. Edwards, F.A. Khan, M.A. Ghatei, and S.R. Bloom Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus Eur. J. Clin. Invest. 27 1997 533 536
146. M.B. Toft-Nielsen, M.B. Damholt, S. Madsbad, L.M. Hilsted, T.E. Hughes, and B.K. Michelsen Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients J. Clin. Endocrinol. Metab. 86 8 2001 3717 3723
147. C. Tourrel, D. Bailbe, M. Lacorne, M.J. Meile, M. Kergoat, and B. Portha Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4 Diabetes 51 2002 1443 1452
148. C. Tourrel, D. Bailbe, M.J. Meile, M. Kergoat, and B. Portha Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age Diabetes 50 2001 1562 1570
149. M.D. Turton, D. O'Shea, I. Gunn, S.A. Beak, C.M. Edwards, and K. Meeran A role for glucagon-like peptide-1 in the central regulation of feeding Nature 379 1996 69 72
150. L.O. Uttenthal, A. Toledano, and E. Blasquez Autoradiographic localization of receptors for glucagon-like peptide-1. (7-36)amide in rat brain Neuropeptides 21 1992 143 146
151. I. Valverde, M. Morales, F. Clemente, M.I. Lopez-Delgado, E. Delgado, and A. Perea Glucagon-like peptide 1: a potent glycogenic hormone FEBS Lett. 349 1994 313 316
152. M.L. Villanueva-Penacarrillo, A.I. Alcantara, F. Clemente, E. Delgado, and I. Valverde Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle Diabetologia 37 1994 1163 1166
153. M.L. Villanueva-Penacarrillo, L. Marquez, N. Gonzalez, M. Diaz-Miguel,
154. T. Vilsboll, H. Agersoe, T. Krarup, and J.J. Holst Similar elimination rates of GLP-1 in obese type diabetic patients and healthy subjects J. Clin. Endocrinol. Metab. 88 2003 220 224
155. T. Vilsboll, T. Krarup, C.F. Deacon, S. Madsbad, and J.J. Holst Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients Diabetes 50 3 2001 609 613
156. T. Vilsboll, T. Krarup, S. Madsbad, and J.J. Holst Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects Regul. Pept. 114 2003 115 121
157. Q. Wang, and P.L. Brubaker Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice Diabetologia 45 2002 1263 1273
158. Y. Wang, H.K. Kole, C. Montrose-Rafizadeh, R. Perfetti, M. Bernier, and J.M. Egan Regulation of glucose transporters and hexosa uptake in 3T3-L1 adipocytes: glucagon-like peptide-1 and insulin interactions J. Mol. Endocrinol. 19 1997 241 248
159. Y. Wei, and S. Mojsov Tissue-specific expression of the human receptor for glucagon-like peptide 1: brain, heart, and pancreatic forms have the same amino acid sequences FEBS Lett. 358 1995 219 224
160. A. Wettergren, B. Schjoldager, P.E. Mortensen, J. Myhre, J. Christiansen, and J.J. Holst Truncated GLP-1 (Proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man Dig. Dis. Sci. 38 1993 665 673
161. A. Wettergren, M. Wojdemann, S. Meisner, F. Stadil, and J.J. Holst The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation Gut 40 1997 597 601
162. M.B. Wheeler, M. Lu, J.S. Dillon, X.H. Leng, C. Chen, and A.E. Boyd III Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C Endocrinology 133 1993 57 62
163. Q. Xiao, R. Boushey, D.J. Drucker, and P.L. Brubaker Secretion of the intestinotropic hormone glucagon-like peptide-2 is differentially regulated by nutrients in humans Gastroenterology 117 1999 99 105
164. G. Xu, D.A. Stoffers, J.F. Habener, and S. Bonner-Weir Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 1999 2270 2276
165. S. Yan, D. Marguet, J. Dobers, W. Reutter, and H. Fan Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen Eur. J. Immunol. 33 2003 1519 1527
166. M. Zander, S. Madsbad, J.L. Madsen, and J.J. Holst Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 359 2002 824 830
167. J. Zhou, M.A. Pineyro, X. Wang, M.E. Doyle, and J.M. Egan Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factors J. Cell. Physiol. 192 2002 304 314
168. J. Zhou, X. Wang, M.A. Pineyro, and J.M. Egan Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells Diabetes 48 1999 2358 2366